{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-222762","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2026-05-14T11:12:20+00:00","discovered_at":"2026-05-14T11:15:00.311818+00:00","generated_at":"2026-05-14T11:15:09.625730+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Invivyd Q1 net product revenue $13.7M (+22% YoY); net loss $41.4M; VYD2311 data delayed to Q3 2026","bullets":["Q1 2026 PEMGARDA net product revenue $13.7M, up 22% YoY vs $11.3M.","Net loss $41.4M ($0.13/sh) vs $16.3M ($0.14/sh) in Q1 2025; R&D expense rose to $30.7M.","Cash $184.2M at Mar 31; raised ~$20M via ATM in Apr 2026, extending runway through VYD2311 launch.","DECLARATION trial upsized by ~500 subjects; top-line data now expected in Q3 2026 (shift from mid-year).","IDMC reduced VYD2311 post-dose monitoring from 2 hours to 30 min; in vitro neutralization vs BA.3.2.2 confirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-222762","json":"https://secwatch.observer/filing/0001193125-26-222762.json","markdown":"https://secwatch.observer/filing/0001193125-26-222762.md","text":"https://secwatch.observer/filing/0001193125-26-222762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/0001193125-26-222762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:15:09.625730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}